Skip to main content
Premium Trial:

Request an Annual Quote

George Adam, Christopher Hibberd

Premium
Applera, the parent company of Applied Biosystems and Celera, last week named George Adam to its board, expanding it to 11 members. The move anticipates the retirement of some current board members during the next several years and a need for additional directors if Applied Biosystems and Celera are split into independent companies, each with its own board, Applera said in a statement.
 
In early August, Applera said that it had retained Morgan Stanley to explore alternatives to its current corporate tracking stock structure, including possibly spinning out the two companies [See PM 08/09/07].
 

 

Oxford Genome Sciences this week said Christopher Hibberd has joined its board. Hibberd is currently CEO of Astute Medical. Prior to that, he was senior vice president of corporate development at Biosite where he was responsible for identifying and pursuing strategic business opportunities.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.